AstraZeneca halts Phase III Truqap trial in prostate cancer

UK pharma major AstraZeneca (LSE: AZN) has pulled the plug on a late-stage trial of its AKT inhibitor Truqap (capivasertib) in metastatic castration-resistant prostate cancer, following an independent review that deemed the study unlikely to meet its targets.

The Phase III CAPItello-280 trial was testing a Truqap combo against placebo in more than 1,000 patients with metastatic disease. However, a pre-specified interim analysis found that the combination was unlikely to achieve its dual primary endpoints of improving radiographic progression-free survival and overall survival.

AstraZeneca said the safety profile of Truqap in the study was consistent with earlier trials.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK